| Labatec Pharma SA - Brimonidine Labatec 2 mg/ml, collyre en solution |
| 68527 | | 01 | | Brimonidine Labatec 2 mg/ml | | collyre en solution | | S01EA05 | | Brimonidin | | 18.01.2023 | | |
|
| Composition |
| brimonidini tartras 2 mg corresp. brimonidinum 1.3 mg, poly(alcohol vinylicus), natrii chloridum, natrii citras dihydricus, acidum citricum monohydricum, benzalkonii chloridum 50 µg, acidum hydrochloridum aut natrii hydroxidum ad pH, aqua ad iniectabile q.s. ad solutionem pro 1 ml. |
| Packungsbestandteile |
| collyre en solution | | | | | | Principe actif | Concentr. |
|---|
| Brimonidine Tartrate | 2 mg/ml correspond Brimonidine 1.3 mg/ml |
| | | | Agents auxilliaires | Concentr. |
|---|
| Citric Acid Monohydrate | | | Acidum Hydrochloridum aut Natrii Hydroxidum ad Ph | | | Benzalkonium Chloride | 50 µg/ml | | Sodium Chloride | | | Natrii Citras Dihydricus | | | Poly(Alcohol Vinylicus) | |
|
|
| numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 5 ml | DDP | DDP | B | | Oui |
|
